Physician profile
Sara L Clouden
NPI 1316111644
$775.76
in general payments reported to CMS, 2019-2025
8 companies · $64.87 in 2025
The $64.87 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.87 · 2022: $129 · 2023: $351 · 2024: $219 · 2025: $64.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $200.38 | 2023-2024 | Endurant Iis, Venaseal |
| E.R. Squibb & Sons, L.L.C. | $181.58 | 2022-2025 | Eliquis, Camzyos |
| Pfizer INC. | $158.49 | 2022-2025 | |
| Silk Road Medical, INC. | $69.33 | 2022-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Smith+Nephew, INC. | $54.92 | 2022-2024 | Collagenase Santyl |
| Solventum Corporation | $44.93 | 2024 | Prevena, V.A.C. Veraflo Cleanse Choice |
| Janssen Pharmaceuticals, INC | $43.50 | 2021-2023 | Xarelto |
| Boston Scientific Corporation | $22.63 | 2025 | Enroute Transcarotid Neuroprotection System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Clouden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.